Everyone deserves the option of better mental health
Small Pharma is a biotechnology company researching and developing short-duration psychedelics with supportive therapy for mental health conditions.
Everyone deserves the option of better mental health
Small Pharma is a biotechnology company researching and developing short-duration psychedelics with therapy for under-served mental health conditions.
Today’s antidepressants leave a third of patients behind. This mental health epidemic needs solutions, not wishful thinking.
Peter Rands
Co-Founder, Small Pharma
We’re on a mission to fast track the development of short-duration psychedelic therapies for patients affected by depression and other mental health conditions .
We believe people deserve treatments that work quickly, have long lasting benefits and are well tolerated. So we're taking a radically different approach.
Who we are,
what we do
Find out more about our story and meet the team behind Small Pharma
‘We do have to start looking for a completely different approach, and try something completely out of the box.’
Dr Carol Routledge, CMSO
Our approach
A novel approach to drug development, by innovating on known compounds to create new and protectable mental health treatments.
Our goal is to develop treatments that provide fast-acting relief, with long-lasting effects, that are scalable in-clinic treatments.
Our goal is to develop treatments that:
provide fast-acting relief
provide long-lasting effects
are scalable in-clinic
Our Approach
Accelerated drug development
We innovate on known compounds. This allows us to accelerate and reduce the risk of early drug development to ultimately speed up progress to trial potential medicines in human clinical trials.
Scalability
We focus on progressing therapies that have the potential to become scalable treatments in critical areas of unmet need, such as depression.
Fast-acting, long-lasting
Our goal is to develop optimized therapies for patients that target better outcomes than current treatments on offer, with rapid and durable relief.
Robust IP protection
We have a robust and multi-layered IP program to protect our innovation.
Our focus is short-duration psychedelics
Psychedelics with supportive therapy may have potential as antidepressant treatments.
Research to date has shown great potential with psychedelics in treating mental health conditions. Psychedelic compounds vary in their duration of subjective effects, often referred to as 'the psychedelic experience', which can range from minutes to more than 12 hours. We want to create scalable in-clinic mental health treatments, so we're focused on short-duration psychedelics with supportive therapy.
Research & trials
Years of R&D development
Medicines in development
Active clinical trials
Investor News
Small Pharma announces further positive data from SPL026 Phase IIa trial in Major Depressive Disorder strengthening topline efficacy results
Statistically significant improvement in anxiety symptoms offers potential in indications beyond depression.
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
The Phase I study will compare IV and IM routes of SPL028 administration.
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
Two new patents approved for issue bringing total to 16 granted patents.
